Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00044889
Other study ID # CLO221
Secondary ID
Status Completed
Phase Phase 2
First received September 6, 2002
Last updated March 17, 2014
Start date May 2002
Est. completion date March 2003

Study information

Verified date March 2014
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens.

This is a single arm, open-label, Phase II study of CLOFARABINE in adult patients with refractory or relapsed acute myelogenous leukemia (AML). Qualified patients must be refractory to one or two induction regimens, or have relapsed < one year from the date of confirmation of the initial complete remission (CR). There will be two phases in this study - an Induction phase and a Consolidation phase.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- note: For inclusion and exclusion criteria, a regimen is defined as including Induction, Consolidation, and Maintenance therapies.

- Diagnosis of AML according to FAB classification

- Must not be eligible for therapy of higher curative potential, and must be in first or subsequent relapse and/or refractory

- A Karnofsky Performance Status (KPS) of greater than or equal to 60.

- If female of childbearing potential, patients must have a negative serum or urine pregnancy test within 7 days of study enrollment. Men and women with reproductive potential must use as an effective contraceptive method while enrolled in the study. Patients must have contraceptive and/or fertility counseling prior to entering the study, i.e., information on sperm banking, etc.

- Signed, written informed consent.

- Ability to comply with study procedures and follow-up examinations.

- Adequate organ function as indicated by specific laboratory values (defined in the protocol), obtained within two weeks prior to registration.

- Classified as AML FAB M3 (Acute Promyelocytic leukemia) and have been treated with at least 2 regimens (a retinoic acid containing regimen and an arsenic trioxide containing regimen) before being considered for this study.

Exclusion Criteria:

- note: For inclusion and exclusion criteria, a regimen is defined as including Induction, Consolidation, and Maintenance therapies.

- Received previous treatment with CLOFARABINE.

- Received more than two previous induction regimens or cycles for the treatment of AML.

- Relapsed > 1 year.

- Have an active, uncontrolled systemic infection considered opportunistic, life threatening, or clinically significant at the time of treatment.

- Are pregnant or lactating.

- Have psychiatric disorders that would interfere with consent, study participation or follow-up.

- Are receiving any other chemotherapy or corticosteroids. Patients must be off previous therapy for at least two weeks and must have recovered from acute toxicity of all previous therapy prior to enrollment.

- Have any other severe concurrent disease.

- Have symptomatic CNS involvement.

- Have chronic myelogenous leukemia (CML) in lymphoid blast crisis).

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
clofarabine (IV formulation)


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT01200355 - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Phase 4
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT01681537 - Lenalidomide Plus Chemotherapy for AML Phase 1
Completed NCT01385423 - Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) Phase 1
Terminated NCT01193400 - Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years Phase 2
Completed NCT00995332 - Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine Phase 1/Phase 2
Completed NCT00981240 - Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes Phase 1
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00726934 - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients N/A
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT01031498 - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting Phase 2
Completed NCT00789256 - Low Dose Melphalan and Bortezomib for AML and High-Risk MDS N/A
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Completed NCT01020539 - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia Phase 1
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Terminated NCT02203773 - Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) Phase 1